Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEL-AMR: Belatacept for subclinical antibody-mediated rejection after kidney transplantation
2024-516527-13-00Phase 4Authorised
- Sponsor
- Rouen University Hospital
- Start
- Jun 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of belatacept in kidney allograft rejection (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Composite graft outcome at 12 months post-biopsy. Planned start Jun 2025; status: authorised.
02
Drugs
belatacept
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2024-516527-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516527-13-00.